Literature DB >> 25201504

The impact of tumor cell differentiation on survival of patients with resectable esophageal squamous cell carcinomas.

Xue Hou1, Yang-Kui Gu, Xue-Wen Liu, Jian-Hua Fu, Xin Wang, Lan-Jun Zhang, Rong-Zhen Luo, Peng Lin, Hao-Xian Yang.   

Abstract

BACKGROUND: The current American Joint Committee on Cancer staging system considers tumor cell differentiation grade to be a factor in the staging of esophageal squamous cell carcinoma (ESCC) in pathologic T0-3N0M0 cases. However, more data are essential to test its efficacy. We sought to investigate the tumor-node-metastasis categories for which tumor cell grade might affect overall survival in Chinese patients.
METHODS: We conducted a retrospective review of 1,220 patients with ESCC who underwent complete resection between December 1996 and December 2008. Survival was calculated by the Kaplan-Meier method, and the log-rank test was used to assess differences in survival between groups. Subgroup analyses and the Cox proportional hazards model were used to further determine the effect of tumor cell grade on overall survival.
RESULTS: The 5-year survival rates for the G1, G2, and G3 groups of pathologic T2N0M0 ESCC cases were 80.1, 61.9, and 47.4%, respectively (p = 0.015), and these rates in the pathologic T3N0M0 ESCC cases were 66.7, 61.7, and 41.2%, respectively (p = 0.020). However, the differences in the survival of the different tumor cell grade groups of the pathologic T1N0M0 (p = 0.198) and the node positive categories (p = 0.063) were not statistically significant. Multivariate Cox regression analysis confirmed that tumor cell grade independently affected the overall survival of patients with pathologic T2-3N0M0 ESCC.
CONCLUSIONS: The staging of ESCC in the Chinese population should be simplified by omitting tumor cell grade as a variable in patients with pathologic T1N0M0 disease. More data are needed to verify our results.

Entities:  

Mesh:

Year:  2014        PMID: 25201504     DOI: 10.1245/s10434-014-4067-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

Review 1.  Postoperative radiation therapy of pT2-3N0M0 esophageal carcinoma-a review.

Authors:  Yijun Luo; Xiaoli Wang; Jinming Yu; Bin Zhang; Minghuan Li
Journal:  Tumour Biol       Date:  2016-09-18

2.  ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis.

Authors:  Srinivas Vinod Saladi; Kenneth Ross; Mihriban Karaayvaz; Purushothama R Tata; Hongmei Mou; Jayaraj Rajagopal; Sridhar Ramaswamy; Leif W Ellisen
Journal:  Cancer Cell       Date:  2016-12-29       Impact factor: 31.743

3.  The Impact of Tumor Regression on Prognosis After Neoadjuvant Chemoradiotherapy in Surgically Treated Esophageal Adenocarcinoma.

Authors:  D J Crull; M C H Hogenes; R Hoekstra; E M Hendriksen; M J van Det; E A Kouwenhoven
Journal:  Ann Surg Oncol       Date:  2022-01-29       Impact factor: 5.344

4.  Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy.

Authors:  Jingjing Duan; Ting Deng; Guoguang Ying; Dingzhi Huang; Haiyang Zhang; Likun Zhou; Ming Bai; Hongli Li; Huimin Yang; Yanjun Qu; Xia Wang; Yi Ba
Journal:  Jpn J Clin Oncol       Date:  2016-01-26       Impact factor: 3.019

5.  The long-term impact of tumor burden in pT3N0M0 esophageal squamous cell carcinoma: A propensity score-matched analysis.

Authors:  Tingting Li; Xiaobin Fu; Lihua Xiao; Liyu Su; Yaqing Dai; Qiwei Yao; Jiancheng Li
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.